Aspirin
Active ingredient · 3 therapeutic classes
Sold as ASA · Blowfish · Alka-Seltzer · Headache Relief · GOODYS Hangover
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 192
- FDA reports (12 mo)
- 24,870
Overview
Plain-language summary, compiled from the cited regulatory records
Aspirin is a medication classified as an Other Agent for Local Oral Treatment [1]. It is approved for the temporary relief of minor aches and pains associated with conditions such as the common cold, headaches, backaches, muscular aches, and toothaches [1]. It can also provide relief for minor pains stemming from arthritis [1].
This active ingredient is available under various brand names, including GOODYS MAX, Bayer Low Dose, and Alka-Seltzer Original Flavor [1]. In the past 12 months, there have been 24,870 adverse event reports associated with this ingredient [2]. The most frequently reported adverse events include fatigue, diarrhea, off-label use, dyspnea, and nausea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 76 | May 29, 2026 |
| US United States | FDA | 71 | May 15, 2026 |
| CA Canada | Health Canada | 45 | May 15, 2026 |
GBUnited Kingdom· MHRA
76 products
Uses
For the secondary prevention of thrombotic cerebrovascular or cardiovascular disease and following by-pass surgery.
How to take
USUnited States· FDA
71 products
Uses
Uses temporarily relieves minor aches and pains due to: minor pain from arthritis headache menstrual pain pain and feverr of colds toothache muscle pain
How to take
CACanada· Health Canada
45 products
Uses
RIVASA 81 MG EC (acetylsalicylic acid delayed release tablets, ASA) is indicated for: • for reducing the risk of vascular mortality in patients with a suspected acute myocardial infarction; • for reducing the risk of a first non-fatal myocardial infarction in individuals deemed to be at sufficient risk of such an event by their physician.
- There is no evidence for a reduction in the risk of first fatal myocardial infarction. - RIVASA 81 MG EC does not reduce the risk of either cardiovascular mortality or first strokes, fatal or non-fatal. - The decrease in the risk of first non-fatal myocardial infarction must be assessed against a much smaller but not insignificant increase in the risk of haemorrhagic stroke as well as gastrointestinal bleeding.
• for reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction; • for reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction; • for prophylaxis of venous thromboembolism after total hip replacement.
Drug interactions
Known interactions involving Aspirin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL298310806 · revised May 29, 2026
- [2]FDA DailyMed · 10b9a1fc-70d1-44… · revised May 15, 2026 [PDF]
- [3]Health Canada (DPD) · 02420279 · revised April 21, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.